A5017163328- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Ionosphere and magnetosphere dynamics
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
- 3D Printing in Biomedical Research
- Atmospheric Ozone and Climate
- GNSS positioning and interference
- Childhood Cancer Survivors' Quality of Life
- Evolution and Genetic Dynamics
- Cancer, Hypoxia, and Metabolism
- CRISPR and Genetic Engineering
- Family Support in Illness
- Ubiquitin and proteasome pathways
- Innovative Microfluidic and Catalytic Techniques Innovation
- Cancer and Skin Lesions
- Neurofibromatosis and Schwannoma Cases
- Cutaneous Melanoma Detection and Management
- Science, Research, and Medicine
- Sarcoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Family and Disability Support Research
- Immunotherapy and Immune Responses
- Geomagnetism and Paleomagnetism Studies
University of Sheffield
1997-2025
Sheffield Children's NHS Foundation Trust
2018
BAE Systems (Sweden)
2001
Developing and providing the right therapy for patient (or personalized targeted treatments) is key to reducing side-effects improving survival in childhood cancers. Most efforts aiming personalize cancer treatment use genomic analysis of malignancies identify potentially targetable genetic events. But it becoming clear that not all patients will have an actionable change, those do there no additional way determine if treatments be effective. Ex vivo drug screening a laboratory technique...
Abstract. A considerable fraction of the solar wind energy that crosses magnetopause ends up in high-latitude thermosphere-ionosphere system as a result Joule heating, consequences which are very significant and global nature. Often heating calculations use hourly averages electric field, rather than time-varying field. This leads to an underestimation heating. In this paper, we determine magnitude by analysing field data from EISCAT Incoherent Scatter Radar, situated at 67° E magnetic...
With diminishing returns and high clinical failure rates from traditional preclinical animal-based drug discovery strategies, more emphasis is being placed on alternative platforms. Ex vivo approaches represent a departure both models clinical-based strategies aim to address intra-tumoural inter-patient variability at an earlier stage of discovery. Additionally, these could also offer precise treatment stratification for patients within week tumour resection in order direct tailored therapy....
Abstract SUMOylation, the covalent attachment of small ubiquitin-like modifier (SUMO) to target proteins, and its reversal, deSUMOylation by SUMO proteases like Sentrin-specific (SENPs), are crucial for initiating cellular responses hypoxia. However, their roles in subsequent adaptation processes hypoxia such as mitochondrial autophagy (mitophagy) remain unexplored. Here, we show that general particularly SUMO2/3 modification, suppresses mitophagy under both normoxia Furthermore, identify...
Abstract BACKGROUND A substantial number of melanoma patients develop local or metastatic recurrence, and early detection these is vital to maximise benefit from new therapies such as inhibitors BRAF MEK, immune checkpoints. This study explored the use novel DNA copy-number profiles in circulating cell-free (cfDNA) a potential biomarker active disease survival. PATIENTS AND METHODS Melanoma were recruited oncology dermatology clinics Sheffield, UK, cfDNA was isolated stored blood plasma....
// Rami Mäkelä 1 , Ville Härmä 2 Nibal Badra Fajardo 3 Greg Wells Zoi Lygerou Olle Sangfelt 4 Juha Kononen 5 and K. Rantala Misvik Biology Oy, Turku, Finland University of Sheffield, Department Oncology Metabolism, UK Patras, Laboratory General Biology, Greece Karolinska Institutet, Cell Molecular Stockholm, Sweden Docrates Cancer Hospital, Helsinki, Correspondence to: Rantala, email: rantala@misvik.com Keywords: cutaneous apocrine sweat gland carcinoma; ex vivo...
<ns3:p>With diminishing returns and high clinical failure rates from traditional preclinical animal-based drug discovery strategies, more emphasis is being placed on alternative platforms. <ns3:italic>Ex vivo</ns3:italic> approaches represent a departure both models clinical-based strategies aim to address intra-tumoural inter-patient variability at an earlier stage of discovery. Additionally, these could also offer precise treatment stratification for patients within week tumour resection...
Abstract. In the past global, fully coupled, time-dependent mathematical model of Earth's thermosphere/ionosphere/plasmasphere (CTIP) has been unable to reproduce accurately observed values maximum plasma frequency, foF2, at extreme geophysical locations such as Argentine Islands during summer solstice where ionosphere remains in sunlight throughout day. This is probably because seasonal dependence thermospheric cooling by 5.3 µm nitric oxide neglected and photodissociation O2 heating rate...
Abstract AIMS With diminishing returns and common clinical failure rates from traditional preclinical animal-based drug discovery strategies, emphasis is being placed on alternative platforms, such as ex vivo approaches. Such approaches represent a departure both models more clinical-based strategies aim to address intra/inter-patient variability at an earlier stage of discovery. Additionally, they could also offer precise treatment stratification for patients within week surgery direct...
In the past global, fully coupled, time-dependent mathematical model of Earth's thermosphere/ionosphere/plasmasphere (CTIP) has been unable to reproduce accurately observed values maximum plasma frequency, foF2, at extreme geophysical locations such as Argentine Islands during summer solstice where ionosphere remains in sunlight throughout day. This is probably because seasonal dependence thermospheric cooling by 5.3 µm nitric oxide neglected and photodissociation O2 heating rate...
Abstract Introduction Treatment of recurrent and metastatic melanoma has been revolutionised by targeted therapy. Inhibitors mutant BRAF are a systemic treatment offered for patients with stage III/IV who known to carry mutation in BRAF. Currently patients’ status is assessed through molecular analysis tissue specimens. Cell-free DNA (cfDNA) released from tumours can be used non-invasively detect active disease predict survival melanoma. cfDNA also provides method detecting mutations. This...
<sec> <title>BACKGROUND</title> Patients and survivors of childhood cancer may experience negative outcomes following treatment. This result in developmental experiences such as social isolation, academic delays, altered elective participation activities. Opportunities that offer to children who have had are important help mitigate the potential One opportunity is recreational oncology camp (“Camp”); focus this research project Camp Ooch Trillium located Ontario, Canada. </sec>...